Aim: To detect the origin of hepatocellular carcinoma (HCC) recurring and attempt to propose a new recurrent mechanism.
Methods: Orthotopic liver allotransplantation was performed on male rats with HCC- induced by diethylnitrosamine using female donors. Metastatic tumors in transplanted livers were obtained. A DNA probe that exhibits specificity for the rat Y chromosome was generated by using a set of primers specific to murine sry gene. In situ hybridization (ISH) for Y chromosome was used to detected the origin of HCC recurring. Male HCC tissue was designed to be positive control. ISH on female tissue and using non-labeled with DIG probe was thought to be negative control.
Results: Positive marks were seen through ISH for Y chromosome in recurrent tumor tissue and positive control. No signal was detected in both negative controls.
Conclusion: Recurrent HCC after liver transplantation originated from disseminated tumor cells in recipients. Extrahepatic cells homing into liver may be a new HCC recurrence mechanism. Likewise, it implicates that this mechanism is responsible for HCC recurring after hepatectomy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726996 | PMC |
| http://dx.doi.org/10.3748/wjg.v10.i6.903 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Importance: Most patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy.
Objective: To determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone.
Design, Setting, And Participants: This multicenter phase 3 randomized clinical trial randomized patients with HCC 1:1 to sorafenib or SBRT followed by sorafenib, stratified by performance status, liver function, degree of metastases, and macrovascular invasion.
Hematogenous metastasis to the colon from hepatocellular carcinoma: A case report.
Int J Surg Case Rep
October 2024
Department of Pathology, Tobata Kyoritsu Hospital, 2-5-1 Sawami, Tobata-ku, Kitakyushu city, Fukuoka Prefecture 804-0093, Japan.
Introduction and importance: Most extrahepatic metastases of hepatocellular carcinoma (HCC) are to the lungs and bones, metastases to the colon are rare. In the present study, we experienced a case of metastasis to the ascending colon during repeated treatment for HCC. Case Presentation: A 63-year-old man was diagnosed with multiple HCCs (T4N0M0 stage IIIB) associated with portal vein invasion.
View Article and Find Full Text PDFDeep learning based on multiparametric MRI predicts early recurrence in hepatocellular carcinoma patients with solitary tumors ≤5 cm.
Eur J Radiol Open
December 2024
Department of Radiology, Zhongshan Hospital, Fudan University, China.
Article Synopsis
- A study evaluated a deep learning model to predict early recurrence of hepatocellular carcinoma (HCC) in patients with solitary tumors ≤5 cm, using preoperative MRI data.
- Out of 331 patients analyzed, 21.1% experienced early recurrence, with tumor size and deep learning-extracted image features being significant risk factors.
- The deep learning model achieved good prediction performance, indicated by high AUC scores, and a new nomogram was developed for visualization and improved assessment of early recurrence risk.
Efficacy of atezolizumab-bevacizumab combination therapy early after recurrence of hepatocellular carcinoma following resection or ablation with a curative intent.
Ann Gastroenterol
October 2024
Academic Department of Internal Medicine - Hepatogastroenterology Unit, "Agioi Anargyroi" General and Oncology Hospital of Kifisia, National and Kapodistrian University of Athens (Spyridon Pantzios, Antonia Syriha, Ioanna Stathopoulou, Sofia Rellou, Georgia Barla, Ioannis Elefsiniotis).
Background: The pattern of hepatocellular carcinoma (HCC) recurrence after resection/ablation is intrahepatic and/or systemic. The efficacy of atezolizumab-bevacizumab treatment as early therapy after recurrence has not been extensively evaluated.
Methods: We evaluated 32 patients (group A) with early HCC recurrence after resection/ablation and 24 patients (group B) initially diagnosed as Barcelona Clinic Liver Cancer (BCLC)-C, all treated with atezolizumab-bevacizumab.
Antitumor effect of bromo-naphthoquinone associated with tannic acid in triple negative breast cancer cells.
Int J Biochem Cell Biol
December 2024
Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Brazil. Electronic address:
Triple-negative breast cancer (TNBC) is an aggressive type of tumor that tends to recur in women. It is characterized by the absence of hormonal receptors, making it challenging to diagnosis and treatment. In this study, we investigated the anti-tumor effects of a pro-oxidant naphthoquinone derivative called bromo-naphthoquinone (BrNQ) isolated and combined with the antioxidant tannic acid (TA) in order to improve treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!